Risk factors for allergy documentation in electronic health record: A retrospective study in a tertiary health center in Switzerland
Allergology International · 2024-01 · 73 (1) · 143-150
DOI: 10.1016/j.alit.2023.06.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergology International, 2024-01. Verfasst von Maxime Ringwald und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. El…. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Anaphylaxis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Most hospitals use electronic health records (EHR) to warn health care professionals of drug hypersensitivity (DH) and other allergies. Indiscriminate recording of patient self-reported allergies may bloat the alert system, leading to unjustified avoidances and increases in health costs. The aim of our study was to analyze hypersensitivities documented in EHR of patients at Lausanne University Hospital (CHUV). METHODS: We conducted a retrospective study on patients admitted at least 24 h to CHUV between 2011 and 2021. After ethical clearance, we obtained anonymized data. Because culprit allergen could be either manually recorded or selected through a list, data was harmonized using a reference allergy database before undergoing statistical analysis. RESULTS: Of 192,444 patients, 16% had at least one allergy referenced. DH constituted 60% of all allergy alerts, mainly beta-lactam antibiotics (BLA) (30%), NSAID (11%) and iodinated contrast media (ICM) (7%). Median age at first hospitalization and hospitalization length were higher in the allergy group. Female to male ratio was 2:1 in the allergic group. Reactions were limited to the skin in half of patients, and consistent with anaphylaxis in 6%. In those deemed allergic to BLA, culprit drug was specified in 19%, 'allergy to penicillin' otherwise. It was impossible to distinguish DH based on history alone or resulting from specialized work-up. CONCLUSIONS: Older age, longer hospital stays, and female sex increase the odds of in-patient allergy documentation. Regarding DH, BLA were referenced in 4% of inpatient records. Specific delabeling programs should be implemented to increase data reliability and patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. Electronic address: maxime.ringwald@chuv.ch.
- Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
- Data Science & Research, Direction of Informatics Systems, Department of Infrastructures, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Zitieren
APA
Ringwald, M., Moi, L., Wetzel, A., Comte, D., Muller, Y. D., & Ribi, C. (2024). Risk factors for allergy documentation in electronic health record: A retrospective study in a tertiary health center in Switzerland. Allergology International, 73(1), 143-150. https://doi.org/10.1016/j.alit.2023.06.006
Vancouver
Ringwald M, Moi L, Wetzel A, Comte D, Muller YD, Ribi C. Risk factors for allergy documentation in electronic health record: A retrospective study in a tertiary health center in Switzerland. Allergology International. 2024;73(1):143-150. doi:10.1016/j.alit.2023.06.006
BibTeX
@article{Ringwald2024,
author = {Ringwald, Maxime and Moi, Laura and Wetzel, Alexandre and Comte, Denis and Muller, Yannick D and Ribi, Camillo},
title = {Risk factors for allergy documentation in electronic health record: A retrospective study in a tertiary health center in Switzerland},
journal = {Allergology International},
year = {2024},
volume = {73},
number = {1},
pages = {143--150},
doi = {10.1016/j.alit.2023.06.006}
}
EUVIMED